← All Ardelyx, INC filings

Ardelyx, INC 10-Q quarterly reports

Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.

NASDAQ
ARDX
Ardelyx, INC
10-Q: Ardelyx Q3 2025: IBSRELA Soars, XPHOZAH Dips Amid Policy Shift
Ardelyx reports increased total revenue driven by strong IBSRELA sales and milestone payments, but faces a larger net loss and significant XPHOZAH sales decline due to Medicare Part D changes.
NASDAQ
ARDX
Ardelyx, INC
10-Q: Ardelyx Q2: IBSRELA Soars, XPHOZAH Dips on Policy
Ardelyx reports strong IBSRELA sales growth and new financing, but faces increased net losses and challenges for XPHOZAH due to Medicare policy changes.
NASDAQ
ARDX
Ardelyx, INC
10-Q: Ardelyx Reports Strong Q1 2025 Revenue Growth Driven by IBSRELA and XPHOZAH
Ardelyx's Q1 2025 revenue surged, fueled by increased sales of IBSRELA and XPHOZAH, alongside a licensing milestone achievement.
NASDAQ
ARDX
Ardelyx, INC
10-Q: Ardelyx Reports Strong Q3 Revenue Growth, Navigates Regulatory Challenges
Ardelyx's Q3 2024 results show significant revenue growth driven by product sales, while the company addresses regulatory hurdles regarding XPHOZAH's inclusion in the ESRD PPS.
NASDAQ
ARDX
Ardelyx, INC
10-Q: Ardelyx Reports Strong Q2 Revenue Growth Driven by IBSRELA and XPHOZAH Sales
Ardelyx's Q2 2024 results show significant revenue growth, primarily driven by increased sales of IBSRELA and the launch of XPHOZAH.
NASDAQ
ARDX
Ardelyx, INC
10-Q: Ardelyx Reports Strong Q1 2024 Revenue Growth Driven by IBSRELA and XPHOZAH Sales
Ardelyx's Q1 2024 financial results show significant revenue growth, primarily driven by increased sales of IBSRELA and the launch of XPHOZAH.